Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michelle Sidel
Observed name:
Sidel, Michelle
Institution:
Novartis (United States)
Observed institution:
Novartis (United States)
OpenAlex ID:
A5039004247
Review: Clinical Inertia in the Management of Chronic Obstructive Pulmonary Disease
2012
·
Catherine E. Cooke
, Michelle Sidel
, et al.
·
COPD Journal of Chronic Obstructive Pulmonary Disease
·
51
PDF
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
2020
·
Diana G. Wang
, Dulce M. Barrios
, et al.
·
Breast Cancer Research and Treatment
·
42
Real-World Outcomes in Patients with First-Line and Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma
2022
·
Daniel Ahn
, Michelle Sidel
, et al.
·
Future Oncology
·
3
Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.
2020
·
Dulce M. Barrios M.S
, Diana G. Wang
, et al.
·
Journal of Clinical Oncology
·
3
Abstract P1-18-18: Real-world natural history data among patients with PIK3CA-mutant and PIK3CA-wild-type advanced breast cancer
2022
·
Pedram Razavi
, Rohan C Parikh
, et al.
·
Cancer Research
·
2
Real-world treatment patterns and survival of U.S. patients receiving second-line anti-programmed cell death protein-1 therapy for advanced/metastatic esophageal squamous cell carcinoma.
2022
·
Daniel H. Ahn
, Michelle Sidel
, et al.
·
Journal of Clinical Oncology
·
1
193 PD-L1 expression in gastroesophageal cancer: A systematic literature review
2023
·
Zev A Wainberg
, Sasan Jahanian
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
10
Citation count:
102
H-index:
3
I10-index:
2
Year
Topic
Type